Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134739808> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W3134739808 abstract "Cancer is a disease characterised by the uncontrolled growth and spread of abnormal cells, and it is the second leading cause of death globally. The vast majority of patients require chemotherapy in conjunction with surgery or radiological treatments in some steps of their treatment. CLL (Chronic Lymphocytic Leukaemia) is the most common leukaemia in developed countries globally, primarily affecting the elderly. CLL is classed as a clonal disorder of mature B-lymphocytes and its clinical patient prognoses being affected mainly by the mutational status of the Immunoglobulin G Heavy Chain Variable region (IGHV) (with unmutated IGHV holding a better patient prognosis than the wild type variant). We have developed a general procedure for the synthesis of N-substituted 9-nitro-12,14-dioxo-9,10-dihydro-9,10-[3,4]epipyrroloanthracen-13-yl derivatives to study their antiproliferative activity in leukaemia and breast cancer cells. The synthesis of these compounds involves the reaction between (E)-9-(R)-9,10-dihydro-9,10-[3,4]furanoanthracene-12,14-dione and different amines and diamines in acetic acid at 120 ºC. The products were spectroscopically characterised (1H and 13C NMR, HRMS) and the stability profile was determined over pH range 4-9. The effect on cancer cell viability of the compound panel was determined in CLL leukaemia cell lines HG3 (unmutated IGHV), PGA1 (mutated IGHV), ER positive (MCF-7) and triple negative breast cancer cells (MDA-MB-231). The effects on ROS levels was also studied. The dimeric ethanoanthracene 6g was identified as the most potent compound with IC50 9.44 mM (MCF-7) and 0.0017 mM (MDA-MB-231) and with superior activity to fludarabine in CLL cells. 6g is a potential candidate for future development." @default.
- W3134739808 created "2021-03-15" @default.
- W3134739808 creator A5029287111 @default.
- W3134739808 creator A5034101918 @default.
- W3134739808 creator A5037100545 @default.
- W3134739808 creator A5090128810 @default.
- W3134739808 date "2020-11-06" @default.
- W3134739808 modified "2023-09-25" @default.
- W3134739808 title "Synthesis and biological evaluation of new <em>N</em>-substituted 9-nitro-12,14-dioxo-9,10-dihydro-9,10-[3,4]epipyrroloanthracen-13-yl derivatives" @default.
- W3134739808 doi "https://doi.org/10.3390/ecmc2020-07410" @default.
- W3134739808 hasPublicationYear "2020" @default.
- W3134739808 type Work @default.
- W3134739808 sameAs 3134739808 @default.
- W3134739808 citedByCount "0" @default.
- W3134739808 crossrefType "proceedings-article" @default.
- W3134739808 hasAuthorship W3134739808A5029287111 @default.
- W3134739808 hasAuthorship W3134739808A5034101918 @default.
- W3134739808 hasAuthorship W3134739808A5037100545 @default.
- W3134739808 hasAuthorship W3134739808A5090128810 @default.
- W3134739808 hasBestOaLocation W31347398081 @default.
- W3134739808 hasConcept C121608353 @default.
- W3134739808 hasConcept C126322002 @default.
- W3134739808 hasConcept C159654299 @default.
- W3134739808 hasConcept C185592680 @default.
- W3134739808 hasConcept C203014093 @default.
- W3134739808 hasConcept C2777609679 @default.
- W3134739808 hasConcept C2777938653 @default.
- W3134739808 hasConcept C2778461978 @default.
- W3134739808 hasConcept C502942594 @default.
- W3134739808 hasConcept C530470458 @default.
- W3134739808 hasConcept C71240020 @default.
- W3134739808 hasConcept C71924100 @default.
- W3134739808 hasConcept C86803240 @default.
- W3134739808 hasConceptScore W3134739808C121608353 @default.
- W3134739808 hasConceptScore W3134739808C126322002 @default.
- W3134739808 hasConceptScore W3134739808C159654299 @default.
- W3134739808 hasConceptScore W3134739808C185592680 @default.
- W3134739808 hasConceptScore W3134739808C203014093 @default.
- W3134739808 hasConceptScore W3134739808C2777609679 @default.
- W3134739808 hasConceptScore W3134739808C2777938653 @default.
- W3134739808 hasConceptScore W3134739808C2778461978 @default.
- W3134739808 hasConceptScore W3134739808C502942594 @default.
- W3134739808 hasConceptScore W3134739808C530470458 @default.
- W3134739808 hasConceptScore W3134739808C71240020 @default.
- W3134739808 hasConceptScore W3134739808C71924100 @default.
- W3134739808 hasConceptScore W3134739808C86803240 @default.
- W3134739808 hasLocation W31347398081 @default.
- W3134739808 hasOpenAccess W3134739808 @default.
- W3134739808 hasPrimaryLocation W31347398081 @default.
- W3134739808 hasRelatedWork W1965035229 @default.
- W3134739808 hasRelatedWork W2109137997 @default.
- W3134739808 hasRelatedWork W2558062410 @default.
- W3134739808 hasRelatedWork W2558613206 @default.
- W3134739808 hasRelatedWork W2582299606 @default.
- W3134739808 hasRelatedWork W2606039306 @default.
- W3134739808 hasRelatedWork W2748952813 @default.
- W3134739808 hasRelatedWork W2899084033 @default.
- W3134739808 hasRelatedWork W2913288684 @default.
- W3134739808 hasRelatedWork W344354797 @default.
- W3134739808 isParatext "false" @default.
- W3134739808 isRetracted "false" @default.
- W3134739808 magId "3134739808" @default.
- W3134739808 workType "article" @default.